- €445.36m
- €510.81m
- €65.43m
French and Benelux stocks-Factors to watch on September 15
Brief: Genfit SA - Advances Nangibotide In Phase 2 Clinical Investigation In Aclf
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Genfit March 31 Cash And Cash Equivalents EUR 136.1 Million
Brief: Genfit Posts FY 2025 Revenue Of 65.4 Million Euros
Brief: GENFIT SA Says Phase 1 Results Confirm G1090N Has A Favorable Safety And Tolerability Profile
French and Benelux stocks-Factors to watch 21 Nov
Brief: Genfit Announces Effectiveness Of Delisting Of American Depositary Shares From Nasdaq
Brief: Genfit Announces Intention To Voluntarily Delist American Depositary Shares From The Nasdaq Global Select Market
Brief: Genfit Reports First-Half 2025 Financial Results
Brief: Genfit H1 Operating Income EUR 76 Thousand
Brief: GENFIT Announces Discontinuation of Its VS-01 Program in ACLF
Brief: Genfit Completes Royalty Financing Of Eur 185 Mln With HCRx
Brief: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
Brief: Genfit Says Closing Of Royalty Financing And €130 Million Installment Expected Shortly
Brief: Genfit Says Revenues Amounted To €67.0 Million As Of Dec 31, 2024
Brief: Genfit Announces The Amendment Of The Final Terms Of The Dual Proposal To The 2025 Oceanes Holders
Brief: Genfit Outlines Anticipated New Clinical Trial Initiations, Development Milestones And Data Readouts In 2025
Brief: GENFIT Signs Royalty Financing Deal With HealthCare Royalty For Up To EUR 185 Mln